© Reuters.
Shares of Safety Shot, previously known as Jupiter Wellness, saw an uptick of over 11.77% on Thursday, following the release of a study that suggests its beverage could help reduce blood alcohol concentration (BAC) levels. This recent surge adds to the firm’s remarkable annual growth of 123%.
The study, albeit loosely supervised, involved volunteers consuming alcohol for an hour, then pausing for 30 minutes before undergoing sobriety tests and breathalyzer measurements. After the consumption of Safety Shot and another half-hour wait, these tests were repeated. The results indicated that individuals who consumed Safety Shot experienced an average BAC reduction rate of 0.079% per hour. In contrast, the control group’s reduction rate stood at only 0.01% per hour.
The beverage in question was procured from GBB Drink Lab in July 2023. Glynn Wilson, Safety Shot’s Chief Scientific Officer, announced on Thursday that a double-blinded placebo-controlled clinical trial is underway to generate more credible data regarding the drink’s efficacy.
The company’s stock performance and the promising initial results from the study have sparked interest among investors and consumers alike. However, the scientific community and market watchers will be keenly awaiting the results of the upcoming clinical trial for more definitive proof of the product’s effectiveness.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.
Read the full article here
